IPOs

Morphic Holding prices upsized IPO at $15 midpoint

Morphic Holding, a preclinical biotech developing oral integrin inhibitors for chronic diseases, raised $90 million by offering 6 million shares at $15, within the range of $14 to $16. The company originally planned to sell 5 million shares. Morphic Holding plans to list on the Nasdaq under the symbol MORF. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as lead managers on the deal.

Morphic Holding prices upsized IPO at $15 midpoint

Investment Disclosure: Renaissance IPO ETF (symbol: IPO) Renaissance International ETF (symbol: IPOS)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.